Platinum resistance biochemical markers  may be useful for choosing a rational tactics of oncological treatment of patients with recurrent ovarian cancer.  One of the most reliable markers is ERCC1.  We conducted a retrospective study on a group of patients with recurrent platinum-resistant ovarian cancer who underwent suboptimal cytoreduction and HIPEC, followed by second look surgery with complete cytoreduction. A significant decrease in the expression of ERCC1 in tumor cells under the influence of hyperthermia was found, which may indicate a decrease in resistance to platinum drugs.

Mykhailo Chetverikov has completed his MD at  Odesa national medical univercity, Ukraine. He is the PHD program scientist of obstetrics and gynecology department of Odesa national medical univercity, Ukraine. His main research field currently is recurrent ovarian cancer. He is leading oncologist of the “Esperanto MED” medical center, Ukraine.